AXP107-11 in Combination With Standard Gemcitabine (Gemzar® ) Therapy for Treatment in Patients With Pancreatic Cancer



Phase 1/Phase 2

Unknown status
The purpose of this study is to assess the effect and safety of AXP107-11 alone, and in combination with gemcitabine standard therapy, in patients with advanced or metastatic cancer of the pancreas. The safety, pharmacokinetics and efficacy of AXP107-11 in these patients will also be studied.
Nov 30,2010
18 Years

In order to facilitate the use of our website, we use cookies.

Please confirm if you accept our tracking cookies. When declining the cookies, you can continue visiting the website without sending data to third party services. Read our complete cookie statement here.